Silver, R.M., Fox, K.A., Barton, J.R., Abuhamad, A.Z., Simhan, H., Huls, C.K., Belfort, M.A. and Wright, J.D. (2015) Center of Excellence for Placenta Accreta. American Journal of Obstetrics & Gynecology, 212, 561-568.
https://doi.org/10.1016/j.ajog.2014.11.018

has been cited by the following article:

• TITLE: Modified Triple P Approach by Gynecologic Oncologist-Led Team for Placenta Accreta Spectrum Improves the Outcome: Non-Randomized Controlled Trial

  AUTHORS: Mohammad Am Ahmed, Mostafa M. Khodry

  KEYWORDS: Placenta, Accreta, Gynecologic, Oncologist, Surgery, Outcome

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.9 No.7, July 25, 2019

  ABSTRACT: Introduction: Placenta Accreta Spectrum (PAS) is associated with significant maternal and fetal morbidity and mortality. The ideal conservative management still does not exist. We aimed to compare the outcome of cesarean section for PAS by a gynecologic oncologist-led team using the modified triple P approach and by a non-gynecologic oncologist-led team. Material and Methods: This is non-randomized controlled trial. Group A had Cesarean Section by gynecologic oncologist. Gynecologic oncologist-led team did all Cesarean Section following a modified triple P approach. The first P is for “Plan” the uterine incision. The second P for “Pelvic” devascularization by internal iliac artery ligation. The third P is for Placenta non-separation with resection of the myometrium. Group B had Cesarean Section by non-gynecologic oncologist-led team. The main outcome measures were the need for hysterectomy, amount of blood loss, and the management-related complications. Results: Group A had significantly less estimated blood loss, and received less number of backed RBCs units, and less operative time than group B. The uterus is preserved in all cases of group A and in 50% of cases of group B. The overall maternal morbidity rate was 17.5% in group A and 72.2% in group B. Conclusion: This study provides evidence that the modified triple P approach for PAS by gynecologic oncologist-led team presents lower maternal morbidity in comparison to surgery by non-gynecologic oncologist-led team.